Clinical Trials
422 trialsDynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
VERDI
Dana-Farber Cancer Institute
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
TTBF
University of California, San Francisco
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Peking University Cancer Hospital & Institute
IRMK01
University Hospital, Bordeaux
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Advanced Diffusion Imaging in Renal Cancer Patients
NYU Langone Health
SLM + Axitinib for Clear Cell RCC
University of Iowa
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
NORDIC-SUN
University of Aarhus
LIAM Mc
University College Cork
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
COSTAR-002
Peking University First Hospital
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Rein3DP-M
University Hospital, Bordeaux
NEOPAX
University of Colorado, Denver
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SPARCC
Dana-Farber Cancer Institute
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
Chang Gung Memorial Hospital
NAMECAR
Institut Paoli-Calmettes
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Institut Paoli-Calmettes
MetroWilms
Centre Oscar Lambret
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Centre Oscar Lambret
NeuroPrevPTSD
Centre Oscar Lambret
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
68Ga-PSMA PET in the Renal Cell Carcinoma
Xijing Hospital
CAIX PET/CT
Massachusetts General Hospital
CALySSEY
Baylor College of Medicine
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Ankara University
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
LASER
Dana-Farber Cancer Institute
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
University of California, San Francisco
EBNK-ST-001
Essen Biotech
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
SMILe
University Hospital, Linkoeping
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Dana-Farber Cancer Institute
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center